See more : RXR Acquisition Corp. (RXRAU) Income Statement Analysis – Financial Results
Complete financial analysis of Formosa Pharmaceuticals, Inc. (6838.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Formosa Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- DKS Co. Ltd. (4461.T) Income Statement Analysis – Financial Results
- DFV Deutsche Familienversicherung AG (DFV.DE) Income Statement Analysis – Financial Results
- iBrands Corp. (IBRC) Income Statement Analysis – Financial Results
- Consolidated Edison, Inc. (ED) Income Statement Analysis – Financial Results
- Deccan Cements Limited (DECCANCE.NS) Income Statement Analysis – Financial Results
Formosa Pharmaceuticals, Inc. (6838.TWO)
About Formosa Pharmaceuticals, Inc.
Formosa Pharmaceuticals, Inc., a late-preclinical and early clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007, an aqueous-based ophthalmic nanosuspension that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-0110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002, a topical antibiotic for infectious eye diseases, such as blepharitis; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer, as well as lung fibrosis. It has a collaboration agreement with Eyenovia, Inc. for the development of novel ophthalmic therapeutic. The company was founded in 2010 and is headquartered in Taipei City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 31.17M | 1.32M | 28.53M | 0.00 |
| Cost of Revenue | 3.83M | 982.00K | 267.00K | 0.00 |
| Gross Profit | 27.35M | 333.00K | 28.26M | 0.00 |
| Gross Profit Ratio | 87.73% | 25.32% | 99.06% | 0.00% |
| Research & Development | 270.18M | 356.47M | 387.62M | 216.29M |
| General & Administrative | 40.20M | 25.53M | 20.65M | 17.31M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 40.20M | 25.53M | 20.65M | 17.31M |
| Other Expenses | -25.15M | -24.41M | -16.26M | 13.08M |
| Operating Expenses | 310.38M | 382.00M | 408.27M | 233.60M |
| Cost & Expenses | 314.21M | 382.98M | 408.54M | 233.60M |
| Interest Income | 12.42M | 474.00K | 55.00K | 477.00K |
| Interest Expense | 4.31M | 992.00K | 2.21M | 102.00K |
| Depreciation & Amortization | 40.54M | 39.40M | 37.73M | 36.07M |
| EBITDA | -255.22M | -366.20M | -358.49M | -183.98M |
| EBITDA Ratio | -818.74% | -27,847.91% | -1,256.57% | 0.00% |
| Operating Income | -295.76M | -405.60M | -396.22M | -220.05M |
| Operating Income Ratio | -948.79% | -30,844.18% | -1,388.81% | 0.00% |
| Total Other Income/Expenses | -17.03M | -24.92M | -18.41M | -102.00K |
| Income Before Tax | -300.07M | -406.59M | -398.42M | -220.15M |
| Income Before Tax Ratio | -962.61% | -30,919.62% | -1,396.55% | 0.00% |
| Income Tax Expense | 21.86M | -424.00K | 2.40M | -420.00K |
| Net Income | -321.96M | -406.27M | -400.88M | -219.66M |
| Net Income Ratio | -1,032.84% | -30,895.21% | -1,405.18% | 0.00% |
| EPS | -2.59 | -3.75 | -4.21 | -3.00 |
| EPS Diluted | -2.59 | -3.75 | -4.21 | -3.00 |
| Weighted Avg Shares Out | 124.09M | 108.26M | 95.21M | 73.19M |
| Weighted Avg Shares Out (Dil) | 124.09M | 108.26M | 95.21M | 73.19M |
Source: https://incomestatements.info
Category: Stock Reports